Oncolytic virus delivery by the intravenous route to tumor sites can be impeded by specific OV antibodies, neutralizing antibodies, complement proteins, splenic or hepatic sequestration, transfer into and throughout the tumor, cellular antiviral responses and destruction of infected tumor cells by cells of the innate immune system43–46. This evidence concerns the gene VTN and neoplasm.